The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Tanya B. Dorff
Honoraria - Astellas Pharma; Dendreon; Medivation; Pfizer
Consulting or Advisory Role - Bayer; Dendreon; Genentech
Speakers' Bureau - Astellas Pharma; Dendreon; Pfizer
Research Funding - Bristol-Myers Squibb
 
David I. Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Piramal Life Science
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Piramal Life Science
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Jacek K. Pinski
Speakers' Bureau - Astellas Medivation; Bayer; Dendreon; Janssen; Millennium
Research Funding - Aeterna Zentaris
 
Amir Goldkorn
No Relationships to Disclose
 
Sarmad Sadeghi
No Relationships to Disclose
 
Denice Tsao-Wei
No Relationships to Disclose
 
Susan G. Groshen
No Relationships to Disclose
 
Peter Kuhn
No Relationships to Disclose
 
Mitchell E. Gross
No Relationships to Disclose